JUMP Prevalence of Sarcopenia and Chemobrain in Post-cancer Patients

NCT ID: NCT05800535

Last Updated: 2025-11-21

Basic Information

• Recruitment Status: RECRUITING
• Total Enrollment: 100 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2025-02-10
• Study Completion Date: 2029-02-10

Brief Summary

Therapeutic advances in oncology have transformed the prognosis of cancer patients, placing a significant number of them either in a context of recovery or in prolonged remission close to a chronic disease. Thus, the reconquest of a life after cancer becomes possible but raises many challenges for the patient, his entourage, the medical profession and our society. One of the major challenges is the detection and management of treatment side effects for all patients. In addition to the standard organic assessment (glycaemia, creatinine, liver test, blood count), we are mainly interested in muscle deconditioning and cognitive impairment, which are particularly disturbed in these populations. After the evaluation day, patients are referred to the most appropriate structures (Adapted physical activity, sports for health, and rehabilitation at Henry Gabriel Hospital).

JUMP research is part of axis 2 of the 2021-2030 cancer plan: "Limiting sequelae and improving quality of life", through sheets 1 (research) / 6 (access and quality) / 7 (prevention). This leads to the concrete implementation on the territory of adapted care channels in the city: medical structure, physiotherapy, Adapted Physical Activity (APA) structures, associative structures; which makes it possible to develop and strengthen the city-hospital link. Finally, it allows the patient to take ownership and get involved in the project, allowing in the future to make them truly active in they care and to advise and motivate their peers.

This study is non-interventional, it uses research on data that is already collected as part of conventional care, during the JUMP evaluation day.

This study allows the investigators to constitute a cohort of patients to study different parameters related to the disease or to the treatments received.

Our main objective in this study is to describe the muscular and neurocognitive impairment of post-cancer patients evaluated as part of the JUMP program.

Conditions

Cancer; Sarcopenia

Study Design

• Observational Model Type: COHORT
• Study Time Perspective: RETROSPECTIVE

Study Groups

JUMP Cohort

This study concerns adults with cancer treated with chemotherapy, radiotherapy, hormonal therapy or immunotherapy, in remission or cured. Patients took part in the dedicated post-cancer assessment day.

Study of the adverse effects of long-term oncological treatments

Intervention Type: DRUG

Cognitive and muscular evaluation of patients who have received oncological treatments, away from the latest treatments to assess their impacts

Study of the long-term side effects of oncological treatments on the anxiety-depressive and cognitive state of patients

Intervention Type: BEHAVIORAL

Cognitive and anxiety-depressive evaluation of patients who have received oncological treatments, away from the latest treatments to assess their impacts

Interventions

Study of the adverse effects of long-term oncological treatments

Cognitive and muscular evaluation of patients who have received oncological treatments, away from the latest treatments to assess their impacts

Intervention Type: DRUG

Study of the long-term side effects of oncological treatments on the anxiety-depressive and cognitive state of patients

Cognitive and anxiety-depressive evaluation of patients who have received oncological treatments, away from the latest treatments to assess their impacts

Intervention Type: BEHAVIORAL

Eligibility Criteria

Inclusion Criteria

• Age : 18 to 74 years
• localization of the primitive: breast, lung, melanoma, testicle, bladder, kidney, ovary, colon and pancreas, hemopathy
• patient who benefited from the post-cancer assessment day-

Exclusion Criteria

• Under 18years
• Over 74 years
• Patient who did not received any chemical treatment
• Patient who do not wish to participate

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 74 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Hospices Civils de Lyon

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Service de Rhumatologie, Hospices Civils de Lyon, Groupement Hospitalier Lyon Sud

Pierre-Bénite, , France

Site Status: RECRUITING

Countries

France

Central Contacts

Cyrille CONFAVREUX, MD

Role: CONTACT

Cyrille.confavreux@chu-lyon.fr

+334 78 86 12 31

Facility Contacts

Cyrille CONFAVREUX, PR

Role: primary

Cyrille.confavreux@chu-lyon.fr

4 78 86 12 31 ext. +33

Other Identifiers

69HCL23_0177

Identifier Type: OTHER

Identifier Source: secondary_id

813

Identifier Type: -

Identifier Source: org_study_id